TABLE 3.
Multivariable regressions on BBPS total score and adequate bowel cleansing (N=4339).
| Variable | BBPS total score mean ± SD |
Adjusted p-value * | Adequate bowel cleansing †
n (%) |
OR [95% CI] * | |
|---|---|---|---|---|---|
| Prescribed bowel prep: | |||||
| GoLYTELY® | 6.67 ± 1.87 | reference | 430 (84.0%) | reference | |
| Moviprep® | 7.11 ± 1.62 | .004 | 267 (91.1%) | 1.44 [0.85–2.44] | |
| Miralax® with Gatorade® | 7.09 ± 1.64 | <.001 | 2499 (92.5%) | 1.76 [1.24–2.49] | |
| Prepopik®/Clenpiq® | 7.01 ± 1.59 | .18 | 205 (90.7%) | 1.24 [0.70–2.21] | |
| Suprep® | 7.28 ± 1.66 | <.001 | 426 (90.6%) | 1.37 [0.86–2.16] | |
| Magnesium citrate | 6.89 ± 1.56 | .39 | 48 (90.6%) | 1.54 [0.57–4.17] | |
| Osmoprep® | 7.04 ± 1.86 | .27 | 67 (81.7%) | 0.70 [0.36–1.37] | |
| Bowel prep completion: | |||||
| Did not complete prep | 6.89 ± 1.88 | reference | 298 (86.6%) | reference | |
| Fully completed prep | 7.07 ± 1.66 | .23 | 3606 (91.2%) | 1.36 [0.96–1.93] | |
| Unknown | 7.43 ± 1.52 | .07 | 38 (95.0%) | 2.82 [0.64–12.37] | |
| Bowel prep dosing: | |||||
| Day-before dosing | 6.97 ± 1.70 | reference | 2392 (89.4%) | reference | |
| Split dosing | 7.18 ± 1.63 | .001 | 1550 (93.2%) | 1.35 [1.05–1.74] | |
| Procedure in addition to colonoscopy: | |||||
| No | 7.09 ± 1.65 | reference | 2647 (91.6%) | reference | |
| Yes | 6.99 ± 1.74 | .19 | 1295 (89.4%) | 0.82 [0.65–1.04] | |
| Fellow involvement: | |||||
| No | 7.07 ± 1.68 | reference | 3390 (91.0%) | reference | |
| Yes | 6.98 ± 1.66 | .59 | 552 (89.9%) | 0.96 [0.70–1.31] | |
| Withdrawal time: | |||||
| ≥6 minutes | 7.12 ± 1.62 | reference | 3253 (91.5%) | reference | |
| <6 minutes | 7.31 ± 1.68 | .08 | 250 (94.3%) | 1.42 [0.80–2.50] | |
| Unknown | 6.48 ± 1.97 | <.001 | 439 (84.9%) | 0.55 [0.42–0.74] | |
| Age: | |||||
| 18–49 y | 7.11 ± 1.73 | reference | 976 (89.8%) | reference | |
| 50–64 y | 7.08 ± 1.71 | .74 | 1600 (90.8%) | 1.06 [0.79–1.42] | |
| ≥65 y | 6.98 ± 1.61 | .15 | 1366 (91.7%) | 1.09 [0.79–1.50] | |
| Gender: | |||||
| Female | 7.16 ± 1.66 | reference | 2034 (91.5%) | reference | |
| Male | 6.95 ± 1.69 | <.001 | 1908 (90.1%) | 0.82 [0.65–1.02] | |
| Race/ethnicity: | |||||
| Non-Hispanic white | 7.05 ± 1.66 | reference | 2687 (91.0%) | reference | |
| Non-Hispanic black | 6.87 ± 1.78 | .07 | 450 (90.2%) | 0.87 [0.61–1.24] | |
| Latino | 7.05 ± 1.74 | .51 | 373 (87.8%) | 0.71 [0.49–1.02] | |
| Asian | 7.35 ± 1.57 | .002 | 259 (93.2%) | 1.42 [0.85–2.37] | |
| Other/unknown | 7.15 ± 1.65 | .35 | 173 (93.5%) | 1.44 [0.78–2.69] | |
| Primarily language: | |||||
| English speaker | 7.07 ± 1.68 | reference | 3623 (91.0%) | reference | |
| Non-English speaker | 6.92 ± 1.69 | .51 | 319 (89.6%) | 1.08 [0.71–1.66] | |
| Body mass index (kg/m2): | |||||
| <25 | 7.04 ± 1.68 | reference | 1712 (90.2%) | reference | |
| 25–29.9 | 7.13 ± 1.66 | .005 | 1202 (91.6%) | 1.25 [0.96–1.62] | |
| ≥30 | 6.97 ± 1.69 | .60 | 976 (91.0%) | 1.23 [0.93–1.64] | |
| Unknown | 7.29 ± 1.67 | .51 | 52 (94.6%) | 1.72 [0.52–5.70] | |
| Opioid use: | |||||
| No | 7.12 ± 1.62 | reference | 3371 (92.1%) | reference | |
| Yes | 6.69 ± 1.91 | <.001 | 571 (84.3%) | 0.51 [0.39–0.65] | |
| Tricyclic antidepressant use: | |||||
| No | 7.06 ± 1.67 | reference | 3884 (91.1%) | reference | |
| Yes | 6.47 ± 1.99 | .005 | 58 (79.5%) | 0.36 [0.20–0.67] | |
| Type I or II diabetes: | |||||
| No | 7.11 ± 1.67 | reference | 3322 (91.3%) | reference | |
| Yes | 6.79 ± 1.72 | .001 | 620 (88.6%) | 0.76 [0.56–1.03] | |
| Liver cirrhosis: | |||||
| No | 7.07 ± 1.67 | reference | 3886 (91.1%) | reference | |
| Yes | 6.29 ± 1.79 | .005 | 56 (74.7%) | 0.45 [0.24–0.83] | |
BBPS, Boston Bowel Preparation Scale; CI, confidence interval; OR, odds ratio; SD, standard deviation.
*
The multivariable linear and logistic regression models with random effects included all variables in the table.
†
Adequate bowel cleansing was defined as total BBPS score ≥6 with each segment BBPS score ≥2.